Walvax Biotechnology Co., Ltd., a biological pharmaceutical company, engages in the research and development, production, and sale of bio-medicine products in the People’s Republic of China. It offers bio-medicines, such as vaccines, blood products, and others. The company provides Group A and C meningococcal polysaccharide vaccine for children over the age of 2 years and adults to prevent disease caused by the bacteria named neisseria meningitidis groups A and group C; and Group ACYW135 meningococcal polysaccharide vaccine for children above 2 years old to prevent meningococcal disease caused by epidemic Neisseria meningitidis serogroups A, C, Y, and W-135. It also offers Group A, C meningococcal polysaccharide conjugate vaccine for infants from the age of 3 months to 5 years preventing diseases, such as cerebrospinal meningitis and septicemia; haemophilus influenzae type b conjugate vaccine for infants from the age of 2 months to 5 years to induce immunization against infectious diseases, including meningitis, pneumonia, septicemia, cellulitis, arthritis, epiglottitis, etc. In addition, the company offers prefilled syringe dosage form of haemophilus influenzae type b conjugate vaccine. Walvax Biotechnology Co., Ltd. was founded in 2001 and is headquartered in Kunming, the People’s Republic of China.
walvax biotechnology co-a
(300142:Shenzhen Stock Exchange)
Building 9A, Dingyi Tiancheng Residential Quarter
Keyuan Road No. 99
High & New Tech Development Zone
Phone: 86 871 6831 2659
Fax: 86 871 6831 2567www.walvax.com
The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content.
|No competitor information is available for 300142.|
|View Industry Companies|
|Price/Cash Flow||NM||Not Meaningful|
Sponsored Financial Commentaries
To contact WALVAX BIOTECHNOLOGY CO-A, please visit www.walvax.com. Company data is provided by Capital IQ. Please use this form to report any data issues.